ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
ASP Isotopes has successfully closed its previously announced underwritten public offering, selling 2,754,250 shares of common stock at $6.75 per share. This includes the full exercise of the underwriter's option to purchase an additional 359,250 shares. The offering generated gross proceeds of $18.6 million before deducting underwriting discounts and commissions. Canaccord Genuity served as sole bookrunner, while Cantor Fitzgerald & Co. acted as financial advisor. The offering was conducted under a shelf registration statement and Rule 462(b) filing with the SEC.
ASP Isotopes ha concluso con successo l'offerta pubblica di azioni sottoscritta precedentemente annunciata, vendendo 2.754.250 azioni di azioni ordinarie a 6,75 $ per azione. Ciò include l'esercizio completo dell'opzione dells sottoscrittore di acquistare ulteriori 359.250 azioni. L'offerta ha generato proventi lordi di 18,6 milioni di dollari prima di dedurre gli sconti e le commissioni di underwriting. Canaccord Genuity ha servito come unico bookrunner, mentre Cantor Fitzgerald & Co. ha agito come consulente finanziario. L'offerta è stata condotta sotto una dichiarazione di registrazione shelf e la registrazione ai sensi della Regola 462(b) presso la SEC.
ASP Isotopes ha cerrado con éxito su oferta pública de acciones previamente anunciada, vendiendo 2,754,250 acciones de acciones ordinarias a $6.75 por acción. Esto incluye el ejercicio completo de la opción del suscriptor para comprar 359,250 acciones adicionales. La oferta generó ingresos brutos de $18.6 millones antes de deducir descuentos y comisiones de suscripción. Canaccord Genuity actuó como único bookrunner, mientras que Cantor Fitzgerald & Co. actuó como asesor financiero. La oferta se realizó bajo una declaración de registro y una solicitud bajo la Regla 462(b) ante la SEC.
ASP Isotopes는 이전에 발표된 공모주의 청약을 성공적으로 마무리하고 2,754,250주의 보통주를 주당 6.75달러의 가격으로 판매했습니다. 여기에는 추가로 359,250주를 구매할 수 있는 인수자의 선택권 완전 행사도 포함되어 있습니다. 이번 공모는 인수 수수료와 할인 등을 공제하기 전 1860만 달러의 총 수익을 발생시켰습니다. Canaccord Genuity가 단독 북러너 역할을 했고, Cantor Fitzgerald & Co.가 재무 고문으로 활동했습니다. 이번 공모는 SEC에 대한 선반 등록문과 규칙 462(b) 사전 신고에 따라 진행되었습니다.
ASP Isotopes a clôturé avec succès son offre publique de vente d'actions souscrite précédemment annoncée, en vendant 2 754 250 actions à 6,75 $ par action. Cela inclut l'exercice complet de l'option du souscripteur d'acheter 359 250 actions supplémentaires. L'offre a généré des produits bruts de 18,6 millions de dollars avant déduction des réductions et des commissions de souscription. Canaccord Genuity a agi en tant que bookrunner unique, tandis que Cantor Fitzgerald & Co. a joué le rôle de conseiller financier. L'offre a été réalisée sous une déclaration d'enregistrement en étagère et le dépôt de la règle 462(b) auprès de la SEC.
ASP Isotopes hat erfolgreich das zuvor angekündigte öffentliche Angebot mit Festlegung abgeschlossen und 2.754.250 Aktien zum Preis von 6,75 $ pro Aktie verkauft. Dies umfasst die vollständige Ausübung der Option des Konsortiums, zusätzlich 359.250 Aktien zu kaufen. Das Angebot generierte brutto Einnahmen von 18,6 Millionen Dollar vor Abzug von Anwaltsgebühren und Provisionen. Canaccord Genuity fungierte als alleiniger Bookrunner, während Cantor Fitzgerald & Co. als Finanzberater tätig war. Das Angebot wurde gemäß einer Shelf-Registrierungserklärung und der Regel 462(b) bei der SEC durchgeführt.
- Successfully raised $18.6 million in gross proceeds
- Full exercise of underwriter's option indicates strong demand
- Completed offering through established financial institutions
- Potential dilution of existing shareholders' equity
- Additional shares in circulation may pressure stock price
Insights
The successful completion of this
The full exercise of the overallotment option by the underwriter signals strong institutional interest and confidence in the company's prospects. Having both Canaccord Genuity as bookrunner and Cantor Fitzgerald as financial advisor adds credibility to the offering. This fresh capital injection provides ASP Isotopes with enhanced operational flexibility and resources for potential growth initiatives in the isotopes market.
WASHINGTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”) today announced the closing of the previously announced underwritten public offering of shares of its common stock. ASP Isotopes sold 2,754,250 shares of its common stock, which reflects the exercise in full by the underwriter of its option to purchase up to 359,250 additional shares of common stock, at a public offering price of
Canaccord Genuity acted as sole bookrunner for the offering. Cantor Fitzgerald & Co. acted as financial advisor.
The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”) and a related registration statement that was filed with the SEC pursuant to Rule 462(b) under the Securities Act of 1933 (and became automatically effective upon filing). This offering was made only by means of a prospectus and a related prospectus supplement. Copies of the final prospectus supplement, dated November 1, 2024, and the accompanying prospectus, dated June 12, 2024, relating to the offering have been filed with the SEC and made available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ASP Isotopes
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “hope,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including, but not limited to: the impact of general economic, industry or political conditions in the United States or internationally and other important risk factors set forth under the caption “Risk Factors” in the preliminary prospectus relating to the offering, ASP Isotopes’ Annual Report on Form 10-K for the year ended December 31, 2023, and in any other subsequent filings made with the SEC by ASP Isotopes. Any forward-looking statements contained in this press release speak only as of the date hereof, and ASP Isotopes specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
FAQ
How much did ASP Isotopes (ASPI) raise in its November 2024 public offering?
What was the price per share for ASPI's November 2024 public offering?
How many additional shares were purchased through the underwriter's option for ASPI?
Who was the bookrunner for ASPI's November 2024 public offering?
